ArticleInternational journal of clinical oncology2026
Pain response to palliative intent conventional radiotherapy for painful malignant iliopsoas involvement: a multicenter retrospective study.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEvidence regarding the efficacy of palliative-intent conventional radiotherapy (conv-pRT) for painful malignant iliopsoas involvement (PMII), including malignant psoas syndrome (MPS)-related pain, caused by non-bone metastatic lesions remains limited to small, single-center studies. Therefore, we conducted the first multicenter study to evaluate the clinical effectiveness of conv-pRT for PMII/MPS.
methodsWe retrospectively analyzed patients with PMII/MPS treated with conv-pRT between January 2013 and May 2025. Eligible patients received 8 Gy in 1 fraction, 20 Gy in 5 fractions, or 30 Gy in 10 fractions and had pain assessment available at ≥ 4 weeks after treatment initiation. Pain response was evaluated based on changes in pain scores and opioid consumption. Assessments were performed at 7 ± 3, 14 ± 3, 28 ± 7, and 56 ± 14 days from the start of conv-pRT. The best overall response (OR) during follow-up was determined.
resultsA total of 54 patients were included. The median follow-up duration was 115 days (interquartile range, 62-186 days), and the 56-day survival rate was 86.8%. The best OR rate was 61%, including complete response in 24% and partial response in 37%, while 39% were classified as non-responders. Among responders, 91% achieved OR within 4 weeks. The best OR rate was not significantly associated with tumor burden parameters, including axial maximum diameter and clinical target volume, baseline Numerical Rating Scale score, baseline oral morphine equivalent dose, or the conv-pRT schedule.
conclusionConv-pRT provided clinically meaningful pain relief in approximately half of patients with PMII/MPS and may represent an effective palliative treatment option.
Indexed as
Identifiers
42329524What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.